ClinicalTrials.gg
CompletedNCT04111965PRO-176/IUpdated Jul 16, 2025Results posted

Clinical Trial to Compare the Safety and Efficacy of Nanodrop®

A Phase 1/2 interventional study of Nanodrop® and Systane Balance in Dry Eye, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 6 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Propylene Glycol in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Propylene Glycol · Dry Eye Syndromes.

Enrollment
4th of 12
126 · median 87
Started
2020
the only one that year
Phase 1/2
Only one
of the 12
Registered
8th of 12
by date
Lead sponsor
1 of 12
Laboratorios Sophia S.A de C.V.

Among the 12 studies testing Propylene Glycol in Dry Eye Syndromes, this one is the 4th largest by enrollment, is the only one that started in 2020, is the only one in phase 1/2, and was the 8th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 12 studies testing Propylene Glycol in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About Propylene Glycol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Propylene Glycol in Dry Eye Syndromes, or all of them as a file.
02

Study summary

Study design:

Phase I-II clinical trial, comparative, non-inferiority with active control, parallel groups, double blind with randomisation. Safety analysis when completing the visits of the first 12 subjects of the Nanodrop® group, if there are less than 20% of unexpected Events (EA), related to the research product, recruitment is continued until the sample is completed for efficacy analysis

objectives Security: Evaluate the safety of the ophthalmic application of Nanodrop® by quantifying the incidence of unexpected Adverse Events (EA) related to the research product (PI).

Effectiveness: Demonstrate the non-inferiority of Nanodrop® compared to Systane® Balance, in the efficacy of the treatment of patients with dry eye, by means of the Ocular Surface Disease Index (OSDI).

Hypothesis

Security:

H0 = Nanodrop® is safe in its ophthalmic application as it presents an incidence of unexpected adverse events related to the research drug, less than 20% of the population of Nanodrop® safety group.

H1 = Nanodrop® is not safe in its ophthalmic application, as it presents an incidence of unexpected adverse events related to the research drug, exceeding 20% of the population of Nanodrop® safety group.

Effectiveness:

H0 = Nanodrop® is lower than Systane® Balance by more than 5 points in the OSDI test score.

H1 = Nanodrop® is lower than Systane® Balance by 5 points or less in the OSDI test score.

Number of subjects: n = 126 evaluable subjects 63 evaluable subjects per group (both eyes).

Main inclusion criteria: Dry eye diagnosis

Duration of intervention treatment: 28 days Approximate duration of the subject in the study: 35 days

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Dry eye
  • propylene glycol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have the ability to voluntarily grant your signed
  • Power and willingness to comply with scheduled visits treatment plan and other study procedures
  • Be willing to modify the activities of your lifestyle.
  • Be of legal age
  • Women of reproductive age should ensure continuation (initiated ≥ 30 days prior to the signing of the Informed Consent Form or ICF) of using a hormonal method or intrauterine device (IUD) during the study period
  • Present a dry eye diagnosis, defined by:

OSDI ≥ 13 points plus one of the following:

  • Corneal staining with more than 5 sites
  • Conjunctival staining with more than 9 sites
  • Breakup Time of lacrimal film (BUT) \<10 seconds:

Exclusion criteria

Exclusion Criteria:

  • In the case of women: being pregnant, breastfeeding or planning to get pregnant within the study period.
  • Have participated in another clinical research study ≤ 30 days before the scrutiny visit.
  • Having previously participated in this study.
  • Present a Better Corrected Visual Acuity (MAVC) of 20/200 or worse in one of the eyes.
  • Present an added ophthalmological diagnosis of:

Allergic, viral or bacterial conjunctivitis. Anterior blepharitis. Demodex. Eye parasitic infections. Unresolved eye trauma. Healing diseases of the ocular surface. Corneal or conjunctival ulcers. Filamentous keratitis. Neurotrophic keratitis. Bullous keratopathy. Neoplastic diseases on the ocular surface or annexes. Diseases with fibrovascular proliferations on the conjunctival and / or corneal surface.

Diseases in the retina and / or posterior segment that require treatment or threaten the visual prognosis.

Glaucoma

  • Have a management of your dry eye that requires the implementation of stage 2 treatments of the recommendations in the treatment and management by stages for the dry eye disease from the Dry Eye Workshop II of The Tear Film and Ocular Surface Society (DEWS II, TFOS).
  • Have a history of drug addiction or current drug dependence or within the last two years prior to the signing of the Form.
  • Have a history of ocular surgical procedure within the last 3 months prior to the signing of the Informed Consent Form.
  • Be a user of soft or hard contact lenses. You can enter if you can suspend your use during the study, you must turn 15 days without using the contact lens before inclusion.
  • Having another medical condition, acute or chronic, that at the discretion of the researcher could increase the risk associated with participation in the study or administration of the product under investigation, or that could interfere with the interpretation of the results of the study.
  • Present known to the components of the products under investigation.
  • Be or have an immediate family member (for example: spouse, parent / legal guardian, brother or child) who is an employee of the research site or the sponsor, and who participates directly in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Nanodrop® (PRO-176)

    \- Nanodrop®. 0.6% propylene glycol. Ophthalmic emulsion Laboratorios Sophia, S.A. from C.V. Route of administration: Ophthalmic.

    Drug: Nanodrop®

  • Active comparator
    Systane® Balance

    * Systane® Balance. 0.6% propylene glycol. Ophthalmic emulsion Alcon Laboratories, Inc. * Route of administration: Ophthalmic.

    Drug: Systane Balance

Interventions

  • minimum to meet 1 drop 4 times a day, both eyes

    Also known as: PRO-176, Propylene glycol 0.6%

  • minimum to meet 1 drop 4 times a day, both eyes

    Also known as: Propylene glycol 0.6%

06

What researchers measure

Primary outcomes

  1. Ocular Surface Disease Index (OSDI)

    OSDI is a questionnaire designed to measure eye surface irritation with Rasch analysis to produce estimates on a linear interval scale.. The OSDI score ranges from 0 to 100, with higher scores indicating greater severity of symptoms. A score of 0 represents no symptoms, while 100 represents the most severe symptoms.

    Time frame: will be evaluated at the end of the treatment (day 29, final visit)

  2. Percentage of Unexpected Adverse Events (AE) Related to the Research Product

    the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent

    Time frame: during the 29 days of evaluation, including the safety call

Secondary outcomes

  1. Visual Acuity (VA)

    Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.

    Time frame: will be evaluated at the end of the treatment (day 29, final visit)

  2. Epithelial Defects (ED) Fluorescein Stain

    The epithelial defects will be evaluated by fluorescein, it is a discrete variable that will be realized by direct observation, It will be qualified according to the Eye Staining Rating (CTO) of the International Alliance of Clinical Collaboration of Sjögren (SICCA).According to the CTO, grade 0 corresponds to the absence of dotted epithelial erosions (EEP); Grade 1 is defined as the presence of 1-5 EEP; Grade 2 corresponds to 6-30 EEP; and\> 30 EEP will be classified as grade 3. Additionally a qualification point will be added if: 1) EEP is presented in the central portion of the cornea with a diameter of 4mm; 2) filaments are observed and 3) confluent staining patches are observed, including linear stains. A greater score is a worse outcome.

    Time frame: will be evaluated at the end of the treatment (day 29, final visit)

  3. Epithelial Defects (ED) Green Lissamine

    The epithelial defects will be evaluated by green lissamine, it is a discrete variable that will be realized by direct observation, It will be qualified according to the Eye Staining Rating (CTO) of the International Alliance of Clinical Collaboration of Sjögren (SICCA). In the CTO, grade 0 is defined as the presence of 0 to 9 lissamine green staining points in the interpalpebral bulbar conjunctiva (qualifying the temporal and nasal portion separately); grade 1 is defined by the presence of 10 to 32 points; grade 2 by 33 to 100; and grade 3 for\> 100 points. Due to the difficulty of counting individual points in a moving eye, any area ≥ 4mm2 of confluent points is considered\> 100 points. A higher score is a worse outcome.

    Time frame: will be evaluated at the end of the treatment (day 29, final visit)

  4. Incidence of Expected Adverse Events

    the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent

    Time frame: will be evaluated at the end of the treatment (day 29, final visit)

  5. Tear Breakup Time (TBUT)

    brake up time of the tear film One of the first aspects of the tear film that changes when there is an alteration to the ocular surface is its stability. In general, if the corneal or conjunctival surface is damaged, it is unlikely that a stable tear film can be maintained. The most common method to evaluate tear film stability is the evaluation of TBUT with fluorescein. Once the fluorescein is instilled, with the cobalt blue filter the patient is asked not to blink after having blinked 1 to 2 times. The colored precorneal fluorescein layer will change to less fluorescent or non-fluorescent regions. The time that elapses from the last blink to the appearance of these regions is the TBUT. It will be reported in seconds.

    Time frame: will be evaluated at the end of the treatment (day 29, final visit)

07

Results

Posted Jul 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneNanodrop® (PRO-176)Systane® Balance
Started6363
Completed5659
Not completed74

Outcome measures

PrimaryOcular Surface Disease Index (OSDI)

OSDI is a questionnaire designed to measure eye surface irritation with Rasch analysis to produce estimates on a linear interval scale.. The OSDI score ranges from 0 to 100, with higher scores indicating greater severity of symptoms. A score of 0 represents no symptoms, while 100 represents the most severe symptoms.

Time frame:
will be evaluated at the end of the treatment (day 29, final visit)
Reported as:
Mean · score on a scale
Ocular Surface Disease Index (OSDI)
score on a scaleNanodrop® (PRO-176)Systane® Balance
Ocular Surface Disease Index (OSDI)48.9 ± 19.250.3 ± 18.3
PrimaryPercentage of Unexpected Adverse Events (AE) Related to the Research Product

the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent

Time frame:
during the 29 days of evaluation, including the safety call
Reported as:
Number · percentage of unexpected related AE
Percentage of Unexpected Adverse Events (AE) Related to the Research Product
percentage of unexpected related AENanodrop® (PRO-176)Systane® Balance
Percentage of Unexpected Adverse Events (AE) Related to the Research Product23.017.5
SecondaryVisual Acuity (VA)

Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.

Time frame:
will be evaluated at the end of the treatment (day 29, final visit)
Reported as:
Mean · decimal score (Snellen Chart)
Visual Acuity (VA)
decimal score (Snellen Chart)Nanodrop® (PRO-176)Systane® Balance
Visual Acuity (VA)0.89 ± 0.180.90 ± 0.19
SecondaryEpithelial Defects (ED) Fluorescein Stain

The epithelial defects will be evaluated by fluorescein, it is a discrete variable that will be realized by direct observation, It will be qualified according to the Eye Staining Rating (CTO) of the International Alliance of Clinical Collaboration of Sjögren (SICCA).According to the CTO, grade 0 corresponds to the absence of dotted epithelial erosions (EEP); Grade 1 is defined as the presence of 1-5 EEP; Grade 2 corresponds to 6-30 EEP; and\> 30 EEP will be classified as grade 3. Additionally a qualification point will be added if: 1) EEP is presented in the central portion of the cornea with a diameter of 4mm; 2) filaments are observed and 3) confluent staining patches are observed, including linear stains. A greater score is a worse outcome.

Time frame:
will be evaluated at the end of the treatment (day 29, final visit)
Reported as:
Mean · score on a scale
Epithelial Defects (ED) Fluorescein Stain
score on a scaleNanodrop® (PRO-176)Systane® Balance
Epithelial Defects (ED) Fluorescein Stain0.91 ± 0.920.93 ± 1.14
SecondaryEpithelial Defects (ED) Green Lissamine

The epithelial defects will be evaluated by green lissamine, it is a discrete variable that will be realized by direct observation, It will be qualified according to the Eye Staining Rating (CTO) of the International Alliance of Clinical Collaboration of Sjögren (SICCA). In the CTO, grade 0 is defined as the presence of 0 to 9 lissamine green staining points in the interpalpebral bulbar conjunctiva (qualifying the temporal and nasal portion separately); grade 1 is defined by the presence of 10 to 32 points; grade 2 by 33 to 100; and grade 3 for\> 100 points. Due to the difficulty of counting individual points in a moving eye, any area ≥ 4mm2 of confluent points is considered\> 100 points. A higher score is a worse outcome.

Time frame:
will be evaluated at the end of the treatment (day 29, final visit)
Reported as:
Mean · score on a scale
Epithelial Defects (ED) Green Lissamine
score on a scaleNanodrop® (PRO-176)Systane® Balance
Epithelial Defects (ED) Green Lissamine0.83 ± 0.690.85 ± 0.78
SecondaryIncidence of Expected Adverse Events

the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent

Time frame:
will be evaluated at the end of the treatment (day 29, final visit)
Reported as:
Number · percentage of adverse events per group
Incidence of Expected Adverse Events
percentage of adverse events per groupNanodrop® (PRO-176)Systane® Balance
Incidence of Expected Adverse Events7782.5
SecondaryTear Breakup Time (TBUT)

brake up time of the tear film One of the first aspects of the tear film that changes when there is an alteration to the ocular surface is its stability. In general, if the corneal or conjunctival surface is damaged, it is unlikely that a stable tear film can be maintained. The most common method to evaluate tear film stability is the evaluation of TBUT with fluorescein. Once the fluorescein is instilled, with the cobalt blue filter the patient is asked not to blink after having blinked 1 to 2 times. The colored precorneal fluorescein layer will change to less fluorescent or non-fluorescent regions. The time that elapses from the last blink to the appearance of these regions is the TBUT. It will be reported in seconds.

Time frame:
will be evaluated at the end of the treatment (day 29, final visit)
Reported as:
Mean · reported in seconds
Tear Breakup Time (TBUT)
reported in secondsNanodrop® (PRO-176)Systane® Balance
Tear Breakup Time (TBUT)2.28 ± 2.92.02 ± 2.9

Adverse events

Collected over Time frame will be evaluated from day 1 (basal visit) to the final visit day 28 (±1 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nanodrop® (PRO-176)0/63 (0%)0/63 (0%)54/63 (85.7%)
Systane® Balance0/63 (0%)1/63 (1.6%)47/63 (74.6%)
Most frequent serious events
Most frequent serious events
EventNanodrop® (PRO-176)Systane® Balance
COVID-19Respiratory, thoracic and mediastinal disorders0/631/63
Most frequent other events
Showing 10 of 13
Most frequent other events
EventNanodrop® (PRO-176)Systane® Balance
Burning sensationEye disorders37/6323/63
ineffective drugProduct Issues13/6316/63
pruritusEye disorders11/6313/63
blurred visionEye disorders4/6311/63
conjunctival hyperemiaEye disorders8/638/63
headacheNervous system disorders7/631/63
Irritation in the area of instillationEye disorders5/633/63
tearingEye disorders1/635/63
sensation of ocular painEye disorders3/634/63
conjunctivitisEye disorders4/632/63

Baseline characteristics

The manifested adverse events during the conduction of this trial were obtained during trial visits and reported in the electronic CRF, where the clinical team of the center included the information from source documents. These were previously checked by the monitor team, pharmacovigilance specialist, and the medical specialist part of the sponsor's crew to verify concordance with what was stipulated in the protocol.

Age, Categorical
Age, Categorical(Participants)Nanodrop® (PRO-176)Systane® BalanceTotal
<=18 years000
Between 18 and 65 years5357110
>=65 years10616
Age, Continuous
Age, Continuous(years)Nanodrop® (PRO-176)Systane® BalanceTotal
Mean47.8 ± 17.444.6 ± 15.446.18 ± 16.45
Sex: Female, Male
Sex: Female, Male(Participants)Nanodrop® (PRO-176)Systane® BalanceTotal
Female474087
Male162339
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Nanodrop® (PRO-176)Systane® BalanceTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Nanodrop® (PRO-176)Systane® BalanceTotal
Mexico6363126
Intraocular Pressure (IOP)
Intraocular Pressure (IOP)(mmhg)Nanodrop® (PRO-176)Systane® BalanceTotal
Mean13.8 ± 3.112.7 ± 2.513.20 ± 3.41
08

Study locations

6 sites
  • Catarata y Glaucoma de Occidente
    Guadalajara, Jalisco 44160, Mexico
  • Clínica de Investigación en Reumatología y Obesidad S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Jose Navarro Partida
    Guadalajara, Jalisco 45160, Mexico
  • Health Pharma Professional Research S.A. de C.V.
    Mexico City, Mexico City 03100, Mexico
  • Asociación para Evitar la Ceguera en México, I.A.P.
    Mexico City, Mexico City 04030, Mexico
  • Centro Potosino de Investigación Médica SC
    San Luis Potosí City, 78250, Mexico
09

References and documents

Publications

  • Baiza-Duran LM, Munoz-Villegas P, Sanchez-Rios A, Olvera-Montano O. Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial. J Ophthalmol. 2023 Apr 10;2023:1431473. doi: 10.1155/2023/1431473. eCollection 2023. PubMed 37077305 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Dec 2021, 12 months.

Results were first posted in Jul 2025, 3 years 7 months after primary completion.

Of 21 phase 1/2 interventional studies under Dry Eye Syndromes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2019
First posted
Oct 2, 2019
StartActual
Dec 1, 2020
Primary completionActual
Dec 10, 2021
CompletionActual
Dec 10, 2021
Results first posted
Jul 16, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04111965
Responsible party
Sponsor
First posted
Oct 2, 2019
Start date
Dec 1, 2020
Primary completion
Dec 10, 2021
Completion
Dec 10, 2021
Results posted
Jul 16, 2025
Last update
Jul 16, 2025

Study contacts

Leopoldo Baiza Durán, MD
study director · Laboratorios Sophia S.A de C.V.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propylene Glycol

Start the discussion